Bionik Laboratories Appoints Eric Dusseux as CEO

Bionik Laboratories, a robotics company focused on providing rehabilitation and assistive technology solutions, today announced that the board of directors has appointed Dr. Eric Dusseux as chief executive officer.

Prior to joining Bionik, Dr. Dusseux was president of Europe for Auregen BioTherapeutics SA, a 3D bioprinting tissue engineering biotechnology company headquartered in Switzerland. From 2012 to 2016, Dr. Dusseux served as an executive committee member in the corporate strategy department of Sanofi Pasteur, the vaccine division of Sanofi. Before joining Sanofi Pasteur, Dr. Dusseux served as vice president at GSK Biologicals, a division of GlaxoSmithKline, where he was in charge of therapeutic vaccines against cancer.

Dr. Dusseux is a physician specializing in public health. In addition to his bachelors and medical degrees, he holds a master of science in physical chemistry and is a graduate of the Paris-based business school H.E.C.

“His proven entrepreneurial ability to drive commercialization and growth strategy in domestic and international markets, and his experience in building and leading strategic alliances, will be significant assets for Bionik,” said Peter Bloch, chairman of the board of directors of Bionik.  “Eric’s appointment coincides with our efforts to expand our global sales and marketing efforts and develop strategic distribution agreements and partnerships targeting hospital and mass markets.”